Headspace Health Announces Acquisition of AI-Driven Mental Health and Wellness Company, Sayana
12.1.2022 16:50:00 EET | Business Wire | Press release
Headspace Health, the provider of the world’s most accessible, comprehensive digital mental health platform, today announced the acquisition of Sayana, an AI-driven mental health and wellness company. Sayana will expand Headspace Health’s ability to provide personalized self-care content to its growing global member base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005244/en/
Headspace Health announces acquisition of AI-driven mental health and wellness company, Sayana.
Founded in 2018 and backed by Y Combinator in 2020, Sayana has supported users around the world to improve their mental wellness by helping its members become more mindful of the connections between their feelings and events. The Sayana Self-Care app leverages chat-based sessions with an AI persona named Sayana, who encourages users to track their mood along with what influences it. Sayana personalizes users’ experiences based on their check-ins and mood trends, surfacing high-quality content and self-care exercises rooted in cognitive behavioral therapy (CBT), acceptance commitment therapy (ACT) and dialectical behavioral therapy (DBT), as well as breathing exercises. In addition, the Sayana Sleep app helps members to enjoy deep and restful sleep sessions sequenced based on their mood and sleep patterns.
“Amidst a rapidly growing landscape of mental health and wellness apps, Sayana has developed a uniquely engaging member experience backed by world-class AI and machine learning algorithms,” said Russell Glass, CEO, Headspace Health. “Sayana's technology, and most importantly, Sayana’s team, will help us meaningfully advance our product and content strategy as we continue to build the world’s most comprehensive mental health and wellbeing platform.”
On the heels of its recent merger between Headspace and Ginger, Headspace Health is creating an integrated experience to tackle the full spectrum of mental health needs - from prevention to clinical care - all from one platform backed by AI and data science. Today, Ginger leverages AI to support its team of behavioral health coaches, therapists and psychiatrists to ensure quality interactions with members, comprehensive tracking of services, and close collaboration among care providers. Headspace harnesses the power of AI to surface and recommend content in order to foster healthy habit formation. With the addition of Sayana, Headspace Health will advance its capability to personalize member experiences - to better understand, support and improve their feelings and mood.
Sayana founder and CEO Sergey Fayfer will join Headspace Health and take on a product leadership role, along with an experienced team of engineers and designers who will further advance the company’s unique and engaging member experiences.
“Since our inception, we’ve been on a mission at Sayana to put self-care in everyone’s pocket,” said Sergey Fayfer, Founder and CEO of Sayana. “We’re thrilled to bring together our technology, engineering and design expertise to help advance Headspace Health’s efforts to democratize high-quality, affordable mental healthcare around the world.”
The terms of the deal were not disclosed.
About Headspace Health
Headspace Health is the world’s leading provider of mental health and wellbeing solutions. Through our flagship Headspace brand, we’ve touched the lives of over 100 million people in 190 countries through mindfulness tools for managing stress, sleep, and focus. Our enterprise brands, Headspace for Work and Ginger, are distributed through over 3,500 enterprises, including Starbucks, Adobe, Delta Air Lines, and ViacomCBS; and through health plans such as Cigna. Our members and enterprise partners’ employees have access to mindfulness and meditation tools, CBT, coaching, therapy, and psychiatry, ultimately helping them to be healthier and more productive. To learn more about Headspace Health and our family of brands, visit www.headspacehealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005244/en/
Contact information
Victoria Barnes
Sr. Director, Global Communications & Corporate Marketing, Headspace Health
781 249 3738
press@headspacehealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom